Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.

ABSTRACT: Myeloma is heterogeneous at the molecular level with subgroups of patients characterised by features of epigenetic dysregulation. Outcomes for myeloma patients have improved over the past few decades except for molecularly defined high-risk patients who continue to do badly. Novel therapeutic approaches are, therefore, required. A growing number of epigenetic inhibitors are now available including EZH2 inhibitors that are in early-stage clinical trials for treatment of haematological and other cancers with EZH2 mutations or in which overexpression has been correlated with poor outcomes. For the first time, we have identified and validated a robust and independent deleterious effect of high EZH2 expression on outcomes in myeloma patients. Using two chemically distinct small-molecule inhibit

SUBMITTER: Pawlyn C 

PROVIDER: S-EPMC5380911 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature